Risk Stratification of Nodal PTCL

Chonbuk National University

Status: Completed

Conditions: Angioimmunoblastic T-cell Lymphoma; Anaplastic Large Cell Lymphoma, ALK-negative; Peripheral T-Cell Lymphoma, Not Otherwise Specified

Study type: Observational

Funder types: Other

Identifiers

NCT03040206

nodal PTCL

Details and patient eligibility

About

This study is to investigate the prognostic significance of enhanced International Prognostic Index (NCCN-IPI) and post-treatment PET results in patients with newly diagnosed nodal peripheral T-cell lymphoma (PTCL), and establish a risk stratification model for nodal PTCL patients.

Enrollment: 405 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma [ALCL], anaplastic lymphoma kinase [ALK]-negative)
• Patients diagnosed with between January 1, 2004 and April 30, 2016
• initially treated with curative intent
• Patients with standard 18F-fluorodeoxyglucose (FDG) PET or PET-CT data at the time of diagnosis and at the end of primary treatment

Exclusion criteria

• Patients diagnosed with extranodal PTCLs, including followings (extranodal NK/T-cell lymphoma, nasal type; enteropathy-associated T-cell lymphoma; hepatosplenic T-cell lymphoma; subcutaneous panniculitis-like T-cell lymphoma; EBV-positive T-cell lymphoproliferative childhood disorders, and primary cutaneous lymphomas)
• Patients with ALCL-ALK+
• Patients who do not have 18F-FDG PET or PET-CT data either at diagnosis or at the end of treatment available for review

Trial design

405 participants in 1 patient group

Nodal PTCL

Description:

1. newly-diagnosed, pathologically-proven nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma \[ALCL\], anaplastic lymphoma kinase \[ALK\]-negative) between January 1, 2005 and Jun 30, 2016 2. initially treated with curative intent 3. Standard PET or PET-CT data available at the time of diagnosis and at the end of primary treatment